Business Wire

CA-THEOREM-LLC

4.8.2021 12:02:09 CEST | Business Wire | Press release

Share
Theorem, LLC Launches Theorem Orbital, a New Division Providing an End-to-End Suite of Space and Satellite Logistics Services

Theorem, LLC , an innovation and engineering firm that builds custom enterprise software for the world’s most admired brands, today launched Theorem Orbital , a new division focused on end-to-end space logistics and enablement for the Global 2000.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210804005393/en/

“Today, only 100 of the Global 2000 have active space programs, but that number will increase tenfold over the next decade,” said Brady Brim-DeForest, CEO of Theorem. “The space industry can seem intimidating and hard to navigate — we are here to help make navigating it easy and transparent.”

While recent space-related startups have focused primarily on delivering launch-side capability, other aspects of the space industry are experiencing significant growth , and game-changing opportunities have become within reach for even those who have made minimal investments to date. These include bespoke satellite programs focused on activities like earth observation, remote sensing, and satellite-enabled communications and connectivity.

Theorem Orbital will leverage its direct relationships with space launch providers, prime contractors and suppliers, universities, and NGOs, allowing for a wide range of services tailored to clients expanding their existing footprint, or building a space strategy from the ground up. Theorem Orbital’s preferred providers for launch services and space-based data today include Rocket Lab , Virgin Orbit , Firefly Aerospace , and Satellogic .

“Our partnership with Theorem will help further our mission of democratizing access to Earth Observation data,” said Thomas VanMatre, Satellogic’s Vice President of Global Business Development. “The combination of Theorem’s world-class software innovation and engineering capabilities and Satellogic’s unit cost advantage will unlock a multitude of use cases for the commercial market.”

As part of its commitment to opening up access to space as a strategic resource for the enterprise, mid-market, and academic markets, Theorem is also announcing a strategic investment into bluShift Aerospace , the Brunswick, Maine based maker of the Starless Rogue launch platform that is designed to enable a low barrier to entry for a diverse collection of payloads into the suborbital space ecosystem.

"bluShift’s approach to developing cost-effective and sustainable next-generation rocket technology will open up space to new markets," said Sascha Deri, CEO of bluShift Aerospace. "We feel that our mission and philosophy are well aligned with Theorem Orbital's commitment to lowering the barrier to entry for companies beginning to leverage space-based infrastructure in their mid and long-term strategic plans. We're pleased to welcome them as an investor, and excited to collaborate on uncovering opportunities to accelerate the adoption of bluShift capabilities within the enterprise market."

At launch, Theorem Orbital’s initial suite of services will include:

  • Satellite Data & Connectivity Strategy and Planning - Strategy services designed to enable clients to leverage data and connectivity generated by existing satellite infrastructure, as well as planning for proprietary constellations.
  • Advanced-Data Analysis - Real-time satellite imagery and remote communication networks are shifting how construction, agriculture, real estate, retail, travel, and mining industries run their daily operations, quarterly planning, risk management, insurance negotiations, and other major drivers of their bottom line. Data providers like Satellogic are opening new use cases daily — Theorem Orbital can help clients make the most of this rapidly evolving field.
  • Software Platform Development - Theorem Orbital designs and builds advanced proprietary software platforms that bring together advanced space-based data sources with existing internal enterprise data and systems.
  • Hardware Development - Theorem Orbital can assist clients in utilizing Satellogic’s unique hosted payload program to rapidly prototype and fly proprietary and commercial off-the-shelf sensors to meet client requirements.
  • Internet-in-Space - Theorem Orbital can assist clients in establishing their own IoT communications network in space including the design and launch of bespoke constellations through preferred launch providers.
  • Launch - Theorem Orbital partners with preferred providers — including Virgin Orbit, Rocket Lab, SpaceX, and more — in order to enable the launch of custom payloads into low-earth and near-earth orbit.

“The cost of putting satellites into space has been dramatically reduced due to the innovations from launch providers such as SpaceX, Rocket Lab, and others,” said Nicolas Spurlock, Director of Corporate Strategy at Theorem. “Now is the time for large enterprises to invest in building their own space-based infrastructure and gain an advantage in the new Space 2.0 era.”

Start charting your course to space by learning more at theoremorbital.com .

About Theorem

Theorem, LLC is an innovation and engineering firm that builds custom software for companies making bold bets to stay ahead. Through research, lean design, and agile delivery, we make great user experiences accessible to the enterprise. Founded in 2007, Theorem’s global cross-functional product development teams drive technology, process, and cultural transformation. To learn more about how we enable ambitious leaders to build better software, visit www.theorem.co or follow @TheoremCo .

Link:

ClickThru

Social Media:

https://www.facebook.com/theoremteam

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release

For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will

Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 11:48:00 CEST | Press release

Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye